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1. Introduction 
Although medical and surgical treatments often provide adequate solutions for individuals 
with coronary artery disease, an increasing need exists to develop treatment modalities for 
those patients with angina who are unresponsive to medical therapy, have serious coronary 
atherosclerosis, and are not eligible for percutaneous techniques or bypass surgery, a 
condition known as refractory angina pectoris.  
In recent years, alternative experimental therapeutic options (e.g. ranolazine, enhanced 
external counter-pulsation, shock waves) have been proposed in order to alleviate 
symptoms and improve the quality of life in these patients.  
A promising therapeutic option arising from basic research is the use of autologous cells 
directly inoculated into the ischemic heart. Preliminary clinical trial results are encouraging.  
Aim of this chapter is to review the current knowledge on refractory angina, focusing on cell 
therapy from a biological and clinical standpoint. 
2. Definition of refractory angina pectoris 
According to the European Society of Cardiology and the American College of 
Cardiology/American Heart Association refractory angina pectoris is defined as: 
patients with stable angina pectoris, presence of coronary artery disease (CAD) on a recently 
performed coronary angiogram, who despite optimal conventional anti-anginal medical therapy (beta-
blockers, calcium antagonists, short- and long-acting nitrates) have severe angina, functional class 3–
4 according to the Canadian Cardiovascular Society classification (CCS). In addition, the patients are 
not accessible for conventional revascularization procedures such as coronary artery bypass grafting 
(CABG) or PCI (percutaneous coronary intervention). 
A strong limitation of this statement lies however on the consensus of which is the patient 
not suitable for revascularization. Terms such as “patients who are not candidates for 
conventional revascularization intervention”, or even less strict descriptions such as 
“patients who are suboptimal candidates for angioplasty or coronary bypass surgery”, have 
commonly been used by investigators. The lack of standardized criteria not only may 
generate ambiguity but also make challenging to investigate the potential impact of new 
treatments. There are some criteria that allow to put patients into this definition: patients 
who are at high risk for invasive procedures (CABG or PCI) or those who we do not 
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expected to achieve significant and stable results for anatomical reasons, despite the recent 
advancements of bypass surgery (off-pump coronary by-pass surgery, total arterial 
revascularization, etc) and of PCI (drug eluting stents, interventional approaches to a 
degenerated saphenous vein graft using a wide range of distal embolic protection devices 
and potentially new generations of stent grafts). The keystone is probably to put particular 
attention on the individual patients’ history and symptoms. In particular, there are two 
aspects that has to taken into an account: the lack of improvement after optimization of the 
standard medical therapy and the level of patient’s discomfort (in terms of quality of life, 
angina chest pain, shortness of breath, etc).  
 
DEFINITION OF REFRACTORY ANGINA PECTORIS BY THE JOINT STUDY GROUP 
Refractory angina pectoris is a chronic condition characterized by the presence of angina caused by 
coronary insufficiency in the presence of coronary artery disease which cannot be controlled by a 
combination of medical therapy, angioplasty and coronary bypass surgery. The presence of 
reversible myocardial ischemia should be clinically established to be the cause of the symptoms. 
Chronic is defined as a duration of more than 3 months 
3. Epidemiology 
Available estimates suggest that refractory angina pectoris affects between 600,000 and 1.8 
million people in the United States, with as many as 50,000 new cases each year. 
Approximately 30,000 to 50,000 new cases per year are also estimated in continental Europe. 
Canadian Community Health Survey (2000/2001) data suggest that approximately 500,000 
Canadians are living with unresolved angina, but these data are limited by their reliance on 
self-report. The proportion of these patients living with true refractory angina is not known.  
Despite wide variation in methods used to derive population estimates, there is a general consensus 
that the incidence and prevalence of this condition will continue to rise across countries as CAD-
related survival rates continue to increase and populations age.  
The European Society of Cardiology (ESC) Joint Study Group on the Treatment of 
Refractory Angina has stressed the critical importance of systematic evaluation of the 
epidemiology of refractory angina pectoris to more accurately project disease burden and 
related health services demands. Such data point out the high relevance of the problem 
related to the refractory angina pectoris in terms of economic costs and human resource that 
are necessary to face this disease. 
4. Features and diagnosis 
4.1 Anatomo-physiological basis of myocardial ischemia 
The anatomo-pathological base of the refractory angina pectoris is a well-known process 
called atherosclerosis, a chronic inflammatory disease of the artery – in this specific case the 
coronary arteries – that causes the progressive narrowing of the epicardial (and sometimes 
the intramural) coronary arteries by the development of a lesion called atheroma or 
atherosclerotic plaque causing the discrepancy between myocardial blood flow and 
myocardial energetic and oxygen demand, especially during exercise. The latter situation 
leads to the production of a series of biochemical signals such as potassium, lactate, 
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adenosine, bradykinin, and prostaglandins  that could elicit some high threshold nerves 
ending in the myocardium mediating the typical symptomatology of the myocardial 
ischemia (i.e. fatigue, thoracic pain and shortness of breath). Recent evidences suggest that 
both ǂ and ǃ adreno-receptors are involved in the biochemical signaling of myocardial 
ischemia. In particular, while the ǃ-receptor is mainly involved in the sympathetic activation 
during myocardial stress, the ǂ-receptor seems to play a central role in the activation of the 
adaptive process. Furthermore, receptors localized on primary afferents sympathetic 
postganglionic neurones, and dorsal laminae of the spinal cord and of the brainstem are 
involved in analgesia and play a role in vasomotor control.  
The role of the vagus nerve is still not well defined. As observed by DeJongste & coworkers 
while both vagal and sympathetic afferent fibers contribute to the increased activity of 
spinothalamic tract cells. Activation of vagal afferent fibers could modulate the processing 
of information of the thoracic spinothalamic tract cells receiving afferent input from the 
heart, by activating supraspinal pathways and nuclei. Abandoned the old idea that 
activation of vagal afferent fibers may lead to visceral pain, except in the neck and jaw 
regions, now we know that the vagal afferents may serve as an important rapid signaling 
pathway for communicating the immune changes from the periphery to the areas in the 
brain that respond to infection and inflammation. Depending on the integrity of the vagal 
afferent pathway, the release of inflammatory cytokines like interleukin (IL)-1, IL-6, IL-1b, 
and TNFǂ (tumor necrosis factor ǂ), trigger several systemic responses. This reaction 
induces alterations in pain sensitivity and metabolism, hyperthermia, and increased release 
of adrenocorticotropin, glucocorticoids, and liver acute phase proteins. Furthermore, vagal 
afferent stimulation activates the hypothalamus–pituitary–adrenal axis. Finally, the 
activation of this vagal pathway to supraspinal structures, such as the hypothalamus and 
the amygdala, may activate descending antinociceptive pathways that may provide 
projections of a visceral organ against local inflammatory reactions.  
In conclusion the vagus nerve seems to play an important role in the conduction of the pain 
stimulus from the periphery (i.e. ischemic myocardium) to the cortical network and in the 
visceral response to it mediated by different neuro-hormonal pathways. 
4.2 Clinical features  
There is a sort of threshold limit of ischemia that may start the typical complaints of a 
patient suffering from angina. This patient on exercise, or under other circumstances that 
can increase the oxygen demand from the myocardium (i.e. emotions, cold, smoking, etc) 
usually complains a characteristic thoracic pain, specifically precordial pain, or a more 
general thoracic discomfort (that may be constrictive, suffocating, burning) often irradiating 
to the left arm (ulnar side), neck, throat, jaw and upper abdomen (always above the 
umbilicus). This situation may be accompanied with autonomic reflexes: cold sweating, 
nausea, vomiting, ipotension, and in general with an automatic attempting of the patient to 
obtain relief from symptoms by immediately putting himself at rest e stop doing actions that 
was doing when the pain began. 
The vagus nerve is implied in the afferent transmission to the brain (particularly to the limbic 
system) and in the efferent transmission to the visceral components. Also the sympathetic 
arm of the autonomous nervous system plays a role in the afferent and much more in the 
efferent response to ischemia, promoting the “fight or fly” response to stress by increasing 
the release of numerous stress-related hormones (epinephrine, norepinephrine, 
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glucocorticoid, etc).   If the discomfort/pain is severe the patient may experience a terrifying 
sensation of “impending death” that could put him in a serious state of anxiety. 
Typical pattern of a stable chronic angina in that the symptoms generally regress spontaneously at 
rest or by the aid of some medications in less of 20 minutes from the beginning. This is generally 
sufficient to not loose important quantity of myocardial tissue from the ischemic injury. 
Typically, patients with refractory angina  maintain a good left ventricular function.  
Generally speaking, patients with chronic refractory angina differ from the ordinary angina patient in 
three ways: first, patients with chronic refractory angina pectoris maintain their left ventricular 
function despite severe three vessel disease; second, they do not experience severe arrhythmias and 
therefore their mortality is only about 5%; and third, their angina is very debilitating. 
Regarding quality of life, there are several considerations that a physician must take into an 
account. First of all, we know from the history of patients that this disease only allows 
limited activities, and thus his day-by-day life is severely restricted by symptoms. Secondly, 
the psychological impact of the angina is itself cause of stress on patient and on cure-givers. 
For these reasons, any attempt is welcome to improve quality of life in a patient with 
refractory angina. Moreover, any improvement in myocardial perfusion in these patients 
may have a beneficial impact on prognosis.  
 
CLINICAL FEATURES OF CHRONIC REFRACTORY ANGINA PECTORIS 
THORACIC PAIN OR DISCOMFORT ESPECIALLY ON EXERCISE 
RELIEF OF SYMPTOMS BY REST AND/ OR MEDICATION (NITRATES) 
SEVERAL EPISODES OF PAIN IN A DAY 
SEVERELY RESTRICTED DAY-BY-DAY LIFE 
NEGATIVE PSYCHOLOGICAL IMPACT TO THE PATIENT AND FAMILY 
INCREASED SOCIAL COSTS FOR FREQUENT HOSPITALIZATIONS 
4.3 Diagnosis 
The clinical diagnosis of refractory angina pectoris is basically made on symptoms.  
These patients have often a heavy clinical history of coronary artery disease, with several 
repeated percutaneous transluminal coronary angioplasty (PTCA) procedures or one or 
more operations of coronary artery bypass graft surgery (CABG).  
A history of severe stable chronic angina (Canadian Functional Class 3–4) despite optimal 
conventional pharmacological therapy and ineligibility for conventional procedures of 
revascularization identify the patient with refractory angina. Stress and rest imaging modalities 
(stress-echocardiography, SPECT, cardiac MR, PET) are also essential to identify location and extent 
of ischemia in regions of still viable muscle.  
 
DIAGNOSIS OF REFRACTORY ANGINA PECTORIS 
HISTORY OF MYCARDIAL ISCHEMIA 
PREVIUOS CABG AND / OR PTCA 
EVIDENCE OF ISCHEMIA IN VIABLE MYOCARDIUM 
SEVERE STABLE ANGINA PECTORIS (CCS III / IV) ALTHOUGH OPTIMAL 
CONVENTIONAL PHARMACOLOGYCAL THERAPY 
INELIGIBILITY FOR FURTHER REVASCULARIZATION  
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5. Conventional medical management 
The conventional pharmacological treatments for patients suffering from chronic stable 
angina pectoris are aimed to either reduce the oxygen demand by the myocardium and 
improve myocardial perfusion, all of this expecting to lead an improvement in cardiac 
function and relief from symptoms. 
Changes in lifestyle (stop smoking, weight loss if needed and treatment of comorbidities 
such as diabetes, ipertension) are also warranted. Additive measures, such as lipid lowering, 
inhibition of platelet aggregation, and  interference in the renin-angiotensin system have 
also become established treatments for stable angina pectoris.  
5.1 Nitrates 
Nitrates are the first-line option to treat angina and work to promote vasodilation, thus 
decreasing preload and myocardial oxygen demand. They are subject to tachyphylaxis 
phenomenon, so they should be discontinued for at least 8-12 hours a day (generally during 
the night) to maintain their therapeutic effectiveness. Side effects are hypotension, headache, 
metahemoglobin, stomachache. An important contraindication is cerebral ischemia; caution 
should be done in case of assumption of alcohol and some medications (sildenafil). Nitrates 
have not to be suddenly suspended (rebound effect). 
They are administered by different routes of administration: sublingual, spray, IM and IV. 
 
NITRATES 
NYTROGLYCERINE, ISOSORBIDE MONONITRATE, ISOSORBIDE DINITRATE 
5.2 β – Blockers 
Together with nitrates are first-line choice, if no contraindications exist. By virtue of their 
inotrope and chronotrope negative effect they reduce the heart work and oxygen demand 
from myocardium. Net evidence from different clinical trials have demonstrate the 
improvement in the survival rate in patients with coronary artery disease treated with ǃ-
blockers agents; those patient have also decreased the relative risk to suffer from another 
myocardial infarction. Contraindications are severe heart failure, COPD and heart block.  
 
Β- BLOCKERS 
ATENOLOL, METOPROLOL, BISOPROLOL, CARVEDILOL 
5.3 Calcium channel blockers 
This category of drug cause vasodilation by blocking the calcium ions flow in the smooth 
muscular cells of the arteries and less of the veins. They are the first-line option in the 
Prinzmetal’s angina caused by coronary vasospasm; they are also employed in chronic 
stable angina when other agents are contraindicated or ineffective. Some of these agents 
cause tachycardia (niphedipin) while others induce bradycardia (verapamil, diltiazem). 
 
CALCIUM CHANNEL BLOCKERS 
NIPHEDIPIN, AMLODIPIN, NICARDIPIN, VERAPAMIL, DILTIAZEM 
www.intechopen.com
 
Atherosclerotic Cardiovascular Disease 
 
112 
5.4 Other medications 
Antiplatelet agents are useful in the secondary prevention of myocardial infarction. Statins 
are employed in the treatment of dyslipidemia to reduce LDL-C serum levels and improve 
HDL-C ones in order to reduce the progression of the atherosclerotic plaques; they also 
possess antiproliferative and antioxidant properties. ACE inhibitors and ARBs (angiotensin 
receptor blockers) modulate the renin-angiotensin-aldosterone pathway and so they 
improve the left ventricular function reducing the ventricular remodeling. 
 
OTHER AGENTS 
ASPIRIN, CLOPIDOGREL, TICLOPIDINE, ROSUVASTATIN, PRAVASTATIN, 
SIMVASTATIN, CAPTOPRIL, RAMIPRIL, LISINOPRIL, ENALAPRIL, FOSINOPRIL, 
VALSARTAN, LOSARTAN, IRBESARTAN, TELMISARTAN 
5.5 Ranolazine 
Ranolazine, approved by the Food and Drug Administration in 2006, was the first specific 
novel medical therapy available for the treatment of chronic stable angina after the 
introduction of calcium channel blockers, in the 1980s . Ranolazine is a proven antianginal 
agent that, unlike beta-blockers, nitrates, or calcium channel blockers, does not affect either 
heart rate or blood pressure. Its mechanism of action is primarly due the ability to influence 
the Na+ and Ca2+ homeostasis in cardiomyocytes. In particular, ranolazine’s mechanism of 
action primarily involves inhibition of the late Na+ flux. By this effect, ranolazine prevents 
intracellular calcium overload and its subsequent deleterious electrical and mechanical 
effects. Ranolazine attenuates the abnormally prolonged and dysfunctional myocardial 
contraction that increases myocardial oxygen demand and, at the same time, is thought to 
improve coronary blood flow and myocardial oxygen supply by optimizing diastolic 
function. Randomized clinical studies have been performed to test ranolazine’s ability to 
reduce angina symptoms. 
The MARISA (Monotherapy Assessment of Ranolazine in Stable Angina) investigation, a 
double-blind, multicenter, randomized trial in which were involved 191 patients, evaluated 
improvements of stress-induced angina. Exercise testing was performed at the conclusion of 
each treatment phase, during both peak (four hours after dosing) and trough (12 hours after 
dosing) plasma ranolazine concentrations, to assess the sustainability of a clinical response 
and establish a dose-response relationship. The MARISA investigators found that ranolazine 
500 mg, 1000 mg, and 1500 mg twice daily incrementally increased exercise duration relate 
to the assumption of placebo. These improvements were all significant when compared with 
placebo. Furthermore, dose-related increases in exercise duration at peak, as well as trough, 
and peak times to 1 mm ST segment depression, and times to angina onset were also 
demonstrated (P < 0.005). The use of ranolazine is recommended in patients with chronic angina in 
combination with standard therapy. 
6. Shock wave therapy  
Cardiac shock wave therapy (CSWT) is a novel, noninvasive intervention that may 
ameliorate myocardial ischemia and improve cardiac function. Early clinical trials 
performed showed that CSWT alleviated angina symptoms and improved cardiopulmonary 
performances in patients with myocardial ischemia. More and more evidences indicate that 
CSWT may reduce the ischemic burden and provide angina relief by promoting 
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angiogenesis and revascularization in ischemic myocardium. Earlier in vivo animal studies 
and human clinical studies demonstrated that low-energy pulse waves produced by CSWT 
induced a sort of ‘‘cavitation effect’’ (micron-sized violent bubble collapse within and 
outside cells), exerting a mechanical shear force on myocardial and vascular endothelial 
cells. Furthermore, improved regional myocardial blood flow and capillary density were 
also observed.  
Clinical studies corroborated these early findings, as myocardial perfusion in ischemic 
regions was enhanced following CSWT. In a recent study by Yu Wang and colleagues good 
clinical outcomes are reported. Investigators described improved regional cardiac systolic 
function and imaging studies demonstrated increased myocardial blood flow in ischemic 
myocardium, supporting the notion of CSWT-mediated promotion of angiogenesis. In that 
study CSWT procedure was well tolerated, performed without anesthesia, and allowed for 
concurrent monitoring of ECG, blood pressure, and blood oxygen saturation. One important 
limitation of current clinical experience with CSWT is the small number of patients enrolled 
and the relatively short follow-up period. Further larger clinical trials are expected to more 
reliably evaluate the outcomes of this new approach to chronic myocardial ischemia. 
7. Cell therapy in refractory ischemia 
The clinical limitations of the efficiency of conventional approaches justify the search for 
new therapeutic options. Regenerative medicine can be considered the next step in the 
evolution of organ replacement therapy. It is driven largely by the same health needs as 
transplantation and replacement therapies, but aims further than traditional approaches 
(Daar, 2007). In fact, its purpose is not just replacing the malfunctioning organs, but 
providing the elements required for in vivo repair, to devise replacements that seamlessly 
integrate with the living body, and to stimulate and support the body’s intrinsic capacities 
to regenerate and to heal itself (Greenwood, 2006). Tissue ischemia is a promising platform 
for cell-based therapies. Ideally, the induction of vascularisation into an ischemic region 
might decrease the lesion size, prevent loss of cells through apoptosis and might inhibit the 
development of organ failure.  
The increasing knowledge on the role of circulating cells deriving from the bone-marrow, 
called endothelial progenitor cells (EPCs), on cardiovascular homeostasis in physiologic and 
pathologic condition, have prompted the clinical use of these cells to relieve ischemia 
(Krenning, 2009). The biological rational and the initial clinical results of the use of EPCs in 
refractory ischemia will be hereafter discussed.   
7.1 Endothelial progenitor cells 
7.1.1 Biology 
The discovery of bone marrow(BM)-derived endothelial progenitor cells (EPCs) circulating 
in the blood vessel system by Asahara et al. in 1997 has resulted in a new paradigm for 
endothelial regeneration and introduced a potential new approach to the treatment of 
cardiovascular disease. EPCs are adult progenitor cells, which have the capacity to 
proliferate, migrate and differentiate into endothelial lineage cells but they have not yet 
acquired characteristics of mature endothelial cells (ECs) (Urbich, 2004).  
These cells induce neo-vascularization through paracrine stimulation (Yoon, 2005) and 
became incorporated in the wall of newly formed vessels when injected into animal models 
of hind limb ischemia (mouse and rabbits). EPCs cells can be localized in the adult BM 
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(Peichev, 2000), in the peripheral blood (PB) (Asahara, Matsumoto, 2000) and in the human 
umbilical cord blood (UCB) (Pasino, Naruse, Ma, Liew).  
In the adult life, EPCs, are supposed to derive from the hemangioblasts and can be 
expanded ex vivo from CD34+/CD133+/KDR+/CD45+/- cells. EPCs are distinguished in 
“early” and “late” based on the different timing of their appearance and differences in the 
clones shape (Hur, 2004). Yoon and colleagues  demonstrated that the induction of neo-
vascularization by early EPCs in vivo occurs through paracrine stimulation, while late EPCs 
directly contribute to formation of novel vessels. Another distinction between early and late 
EPCs has been established with the finding that early EPCs, also named colony forming 
unit-endothelial cells (CFU-ECs), originate from CD34+/CD133+/KDR+/CD45+ cells in the 
MNCs cellular fraction while late EPCs, also named endothelial colony forming cells (ECFCs) 
originate from CD34+/CD133-/KDR+/CD45- cells (Timmermans, Ingram, Prater). Other cell 
types present in BM and PB mononuclear fractions are considered EPCs. For example, it has 
been shown that CD14+ monocytes have angiogenic activity (Pujol) and that certain subsets 
of T-lymphocytes also behave as EPCs (Asahara, Gehling).  
Stem cells that can be differentiate into EPCs exist in a quiescent state associate with bone 
marrow niches. In the microenvironments EPCs can either remain in an undifferentiated and 
quiescent state or differentiate. Under physiologic conditions only a small number of these 
cells are maintained in peripheral circulation, where they contribute to endothelial and 
vascular homeostasis. In response to vascular injury or physiological stress, EPCs  can be 
mobilized from the BM and recruited to the damage area (Pesce). Increase of peripheral blood 
EPCs can be induced by a variety of signal from the periphery, including angiogenic growth 
factors (VEGF-A, SDF-1, G-CSF) cytokines (GM-CSF), hormones (EPO, estrogen) or drugs 
(statins) and home to areas of ischemic injury, where they integrate into growing vessels 
(Zammaretti, 2005). In fact, EPC levels are generally low in healthy subjects, decrease in chronic 
vascular disease and transiently increase during acute vascular damage (Barsotti, 2009). 
There is evidence that patients with risk factors (diabetes, hypertension, high cholesterol, 
smoking, obesity and metabolic syndrome) have dysfunctional endothelial progenitors; in 
fact their numbers are reduced in the circulation, they have a reduced migratory activity, 
impaired clonogenicity and survival and, thereby, a reduced in vivo neo-vascularization 
capacity. Similar function alteration have been reported in EPCs isolated from aged and/or 
male individuals and from patients with coronary artery disease or ischemic 
cardiomyopathy (Hung, 2009).   
EPC reduction may have different causes, such as an exhaustion of the pool of progenitor 
cells in the bone marrow, a reduced mobilization, survival or differentiation (Barsotti, 2009). 
7.1.2 Role in ischemia 
The advantage of EPCs therapeutic use depends on their ability to integrate into newly 
forming vessels (ECFCs) or to activate neo-vascularization by pararcine mechanisms (CFU-
ECs).  The two distinct, direct and indirect, ways of human EPC types participation to neo-
vascularization process may represents two different modalities for biologically treating 
ischemic disorders at the heart or peripheral levels. In fact, while CFU-ECs have a 
predominantly paracrine angiogenic activity, ECFCs have a modest paracrine effect and 
may be thus useful for long term engrafting into ischemic tissues or promote re-
endothelization of injured vessels (Young, 2007). The positive contribution of EPCs to adult 
neo-vascularization has been considered an useful approach in order to attenuate 
myocardial ischemia in coronary artery disease. For example, when EPCs were delivered in 
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animal models of myocardial ischemia via either systemic administration or direct 
intramyocardial injection, they were found in the infarcted tissue and contributed to neo-
vascularization, thereby diminishing the infarct size (Kawamoto,2006). An important feature 
of EPCs is their ability to promote rapid re-endothelialization of carotid vessels denuded as 
a consequence of balloon-injury (Griese, 2003). One of the principal mechanisms in this 
framework appears to be the release of vasculoprotective molecules, such as nitric oxide 
(NO). In particular, the endothelial-specific NO Synthase (eNOS) exerts pleiotropic 
cytoprotective effects in the vessel wall, reduces oxidative stress, modulates vascular tone 
and platelet adhesion, and impairs the development of atherosclerosis. It has been shown 
that EPCs overexpressing eNOS have an enhanced antiproliferative in vivo effect that 
significantly reduced the neointimal hyperplasia (Kong). A study by Werner at al showed 
that blood levels of CD34+ KDR+ EPCs are inversely correlated with cardiovascular events 
and death from cardiovascular causes. These findings implied that EPCs support the 
integrity of vascular endothelial cells (Werner, 2005). EPCs also exert a significant reduction 
in collagen deposition, apoptosis of cardiomyocytes and cardiac remodeling (Itescu, 2003). 
Finally, Hinkel and co-workers, showed that Embryonic EPCs (eEPCs) exert post-ischemic 
cardioprotection by paracrine factors activating the phosphoinositide 3-kinase  (PI3K)/AKT 
signaling pathway in cardiomyocytes in vitro and in vivo  (after ischemia and reperfusion in 
a preclinical pig model). eEPCs were capable of reducing the amount of adhesive 
inflammatory cells. In particolar they found that Tǃ4, one of the most highly expressed 
AKT-activating factors in their eEPC population, is indeed responsible for cardiomyocyte 
protection. 
7.2 Choice of cell type and source for clinical use 
The observation that bone marrow elements contribute to cardiac repair in the ischemic 
heart served as the rationale for adult bone marrow cell therapy after ischemic event. This 
evidence that precursors of endothelial cells exist within the mononuclear cell fraction of 
adult bone marrow forms the basis for the use of bone marrow mononuclear cells (BMMNCs) 
in clinical trials (Oettgen,2006).  
Many studies were in agreement that administration of autologous cells in the heart is safe, 
and it causes an improvement, although modest, in some clinical endpoints such as left 
ventricular function and clinical status.  
Because the numbers of autologous EPCs from peripheral blood or cord blood are limited, a 
great amount of attention has been directed to autologous whole bone marrow mononuclear 
cells (Zammaretti, 2005). Several investigators have chosen to deliver unfractionated bone 
marrow–derived cells, a technique that has the advantage of minimizing extensive ex vivo 
manipulation of the cells to isolate and expand a selected population of cells (Oettgen, 2006). 
The potential disadvantage of delivering a mixture of cells is that the percentage of cells that 
are therapeutically useful may be small. Moreover, because whole mononuclear cell 
preparations contain monocytic cells, it remains to be determined whether the improvement 
is in part aided by the monocytic cell fraction. A concern in using whole bone marrow 
mononuclear cells is potential unwanted side effects such as growth of bone or fibrosis from 
mesenchymal and stromal stem cells contained in this population (Zammaretti, 2005). An 
alternative strategy is to isolate purer populations of cells that express specific antigens.  
These was clearly demonstrated by comparing in a rat model the administration of total 
MNCs, CD34+ cells, and a higher dose of total MNCs containing the same number of CD34+ 
cells of the stem cell treatment group. The CD34+ cell receiving group was the best in terms 
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of capillary density, fibrosis area, shortening fraction and echocardiographic measurements 
(Kawamoto). Douglas et al.  showed in a randomized trial in patients with intractable 
angina, feasibility, safety and bioactivity of intramyocardial injection of autologous CD34+ 
cells. Despite this, a growing body of evidences suggests that CD133 could be a useful 
marker that identifies a more primitive human progenitor subpopulation compared to 
CD34. Moreover, in addition to haematopoiesis, CD133+ cells have been shown to possess 
endothelial capacity (Bhatia, 2001). Other reports of different groups, (Stamm et al., Pompilio 
et al., Losordo et al.) showed that intramyocardial delivery of purified CD133+ cells is safe; if 
associated with coronary artery bypass grafting (CABG) surgery, it provides beneficial 
effects and if used for refractory myocardial ischemia improves heart perfusion.  
Another study by Freund and coworkers directly compared CD34+ and CD133+ cells 
isolated from 10 individual healthy donors. Although they did not find differences in terms 
of cell expansion properties, they found a greater subpopulation of more committed cells in 
the CD34+ group and a lower long term colony-forming units (LTC-FU). Moreover, CD34+ 
cells contained a higher proportion of erythroid colony-forming cells, whereas the highest 
content of myeloid colony-forming cells were in the CD133+ selected cells (Freund, 2006). 
From all these results we can conclude that CD133 could be a useful antigen to select 
progenitor cells for a therapeutic purpose. 
Many trials focused the attention on mobilizing cells from bone marrow by different 
regimens of growth factors stimulation. While many cytokines have been used in preclinical 
models, at the clinical level only G-CSF received sufficient priority. Use of this factor in 
patients is facilitated by its already available clinical approval to mobilized and collect HSCs 
for hematologic transplantation by apheresis (Pesce, 2011).  
7.3 Route of administration 
The optimal delivery route with regard to safety and efficacy remains to be established. 
Three main route of cell administration of have been described: retrograde via the coronary 
sinus, anterograde intracoronary, intramyocardial (endocavitary/epicardial injections). In 
2005, Vicario et al reported good outcomes with retrograde delivery catheterizing the 
coronary sinus via the brachial vein. However given the scarcity of clinical experiences with 
this technique, its role in therapeutic angiogenesis is unclear.  
Intracoronary delivery (Wang, Lasala) is performed by the direct injection of a suspension of 
cells into the coronary artery of the ischemic (target) area and it is most often used after MI 
and reperfusion attempts rather than in a context of chronic myocardial infarction.  
Direct intramyocardial (IM) injection appears to be the most promising technique due to its 
ability to more closely target the ischemic territory of interest and, potentially, achieve the 
greatest local concentration of the therapeutic solution. Preliminary experiences reported IM 
administration via the epicardial route under direct mini-thoracotomic surgical access after 
an accurate study of the electrophysiological properties of the myocardium to assess the 
target area of ischemic but still viable myocardial tissue (Babin-Ebell, Van Ramshorst J, 
Gowdak, Briguori, Reyes, Hossne, Pompilio). 
 
ROUTE OF DELIVERY ADMINISTRATION OF THE CELLS 
CORONARY ARTERIES (ANTEROGRADE FASHION) 
CORONARY SINUS (RETROGRADE FASHION) 
DIRECT INTRAMYOCARDIAL INJECTION 
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Subsequently, the era of percutaneous direct IM injection was advanced by the introduction 
of an electromechanical mapping and injection catheter using the NOGA system. This 
approach has the potential to be as precise as the direct surgical injection technique, while 
avoiding the risks of general anesthesia, surgery, and painful postoperative recovery (Hung-
Fat Tse, Beeres, Losordo). 
Concerns have been raised about arrythmogenicity of cell therapy. Available trials did not 
show an increased risk of developing serious ventricular rhythm disturbances related to 
direct injection of cells in the myocardium.  
7.4 Overwiew from clinical trials 
On the basis of encouraging results of preclinical studies, various clinical trials have been 
carried out in order to evaluate safety and efficacy of cell therapy in patients with refractory 
ischemic cardiomyopathy, as shown in the table below. 
The clinical experience of cell therapy in a setting of refractory ischemia encompasses up to now 
about 250 patients, 120 involved in phase I/II and 130 in randomized controlled trials (RCTs). 
Hung-Fat Tse et al. conducted the first in-human study to evaluate the safety of intra-
myocardial transplantation of autologous BM-MNCs for eight patients with intractable 
angina. Immediately before bone marrow cell injection, NOGA system was used to perform 
electromechanical mapping of the left ventricle and then to guide the BM-MNCs injections 
to the area of ischemia. The absence of any acute procedural complications or long-term 
sequalae, including ventricular arrhythmia, myocardial damage, or development of intra-
myocardial tumour provided a strong foundation for performing larger and more definitive 
trials. In most trials, EPCs were isolated from the total MNCs population via magnetic 
positive selection of CD34+ or CD133+ cells (Losordo, Babin-ebell, Kovacic, Pompilio, 
Wang). The safety, feasibility, and efficacy of intra-myocardial CD133+ cell transplantation 
have also been established for patients with refractory ischemia as a sole therapy in the 
absence of bypass surgery (Babin-Ebell, Kovacic, Pompilio).  
Although the limited number of patients included in the early trials, there are evidences 
suggesting an improvement in therms of clinical benefits and myocardial perfusion and 
almost all reports has demonstrated acceptable safety profiles. 
Following these reports, four randomized, multicenter trials were performed to evaluate the 
safety and efficacy of different type of bone marrow derived cells compared to placebo or 
best standard care. To our knowledge, there are no published data comparing the effect of 
cell therapy to specific drug for refractory angina. 
Losordo et al. performed a phase I/IIa, double-blind, placebo-controlled, dose-ranging trial 
to evaluate the intra-myocardial transplantation of G-CSF-mobilized CD34+ cells in 24 
patients with intractable angina. Patients were enrolled into 1 of 3 cohorts (5X104, 1X105 and 
5X105 CD34+ cells/kg) versus placebo. Patient-specific procedures included G-CSF injection, 
leukapheresis for cell harvesting, and NOGA-mapping-guided cell injection, all of which 
were well tolerated with no severe adverse events reported. Favorable trends in angina 
frequency, nytroglicerin usage, exercise tolerance and perfusion defect were observed in 
patients administered CD34+ cells compared with patients who received placebo. They 
reported few and evenly distributed serious adverse events. Following these outcomes, a 
phase IIb study is under way in the United States. A recently published trial randomized 
(1:1) 150 patients to receive intracoronary transplantation of autologous bone marrow 
derived CD34+ cells. The target population included patients with class III and IV angina 
refractory to medical treatment and not amenable to revascularization. Serious adverse  
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Authors 
Study 
design 
Delivery Cell type 
Mean FU 
period 
Safety Results 
Hung-Fat 
Tse et al. 
2003 
Phase I (8) IMendo BM-MNCs 3 months
no AEs 
reported 
↓ angina 
episodes 
↑ perfusion 
Vicario et 
al. 2005 
Phase I (14) IV 
BM-derived 
CD31+ cells 
6 months
chest pain 
during 
procedure (x2)
↑ perfusion 
↓ CCS class 
↑ collateral 
vessels 
↑ QoL 
Briguori et 
al. 2006 
Phase I (10) IMepi BM-MNCs 1 year 
acute AF 7 
days after 
procedure (x1)
↓ CCS class 
↑ LVEF 
↑ QoL 
↑perfusion 
Losordo et 
al. 2007 
RCT phase 
II (18/6) 
IMendo 
mPB-derived 
CD34+ cells 
12 
months 
SAEs evenly 
distributed 
↓ CCS class 
↓ angina 
episodes 
Tse et al. 
2007 
RCT phase 
II (19/9) 
IMendo BM-MNCs 
19 
months 
carcinoma of 
the urinary 
bladder (x1) 
↑ exercise 
time 
↑ LVF 
↓ angina 
episodes 
Table 1. Clinical trials of stem cell therapy in refractory angina 
 
 
Authors 
Study 
design 
Delivery Cell type 
Mean FU 
period 
Safety Results 
Babin-Ebell 
et al. 2008 
Pilot (6) IMepi 
BM-derived 
CD133+ cells 
6 months
no AEs 
reported 
↓ CCS class 
↑ LVEF 
Gowdak et 
al. 2008 
Phase I (8) IMepi BM-MNCs 6 months
no AEs 
reported 
↓ CCS class 
↑ perfusion 
Kovacic et 
al. 2008 
Phase I and 
II (36) 
IC 
mPB-derived 
CD133+ cells vs 
MNCs 
3 months
cardiac 
ischemia (x4), 
thrombocytop
enia(x2) and 
gout(x1) 
↓ angina 
episodes 
↑ perfusion 
Pompilio et 
al. 2008 
Pilot (5) IMepi 
mPB-derived 
vs BM-derived 
CD133+ cells 
24 
months 
no AEs 
reported 
↓ CCS class 
↑ perfusion 
↓ angina 
episodes 
Jan van 
Ramshorst  
et al. 2009 
RCT phase 
II 
(25/25) 
IMepi BM-MNCs 
3 - 6 
months 
pericardial 
effusion after 
procedure (x1)
↓ CCS class 
↑ LVEF 
↓ SSS 
↑ QoL 
Table 2. Clinical trials of stem cell therapy in refractory angina
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Authors 
Study 
design 
Delivery Cell type 
Mean FU 
period 
Safety Results 
Reyes et al. 
2009 
Phase I (14) IMepi BM-MNCs 7 months
no AEs 
reported 
↓ CCS class 
Hossne et 
al. 2009 
Pilot (8) IMepi BM-MNCs 
12-18 
months 
no AEs 
reported 
↓ CCS class 
↑ perfusion 
Wang et al. 
2010 
RCT phase 
II  
(56/56) 
IC 
BM-derived 
CD34+ cells 
6 months
no AEs 
reported 
↓ angina 
episodes 
↓ CCS class 
↑ perfusion 
Lasala et al. 
2011 
Phase I (10) IC 
BM-MNCs vs 
BM-MSCs 
6 months
no AEs 
reported 
↑ LVEF 
↑ perfusion 
↑ QoL 
FU: follow-up; IV: intra-venous; BM: bone-marrow; QoL: Quality of Life; IMendo: endocavitary intra-
myocardial injection; BM-MNCs: bone marrow-derive mononuclear cells; AEs: adverse events; IMepi: 
epicardial intra-myocardial injection; LVEF: left ventricle ejection fraction; RCT: randomized controlled 
trial; SSS: summed stress score; AF: atrial fibrillation; LVF: left ventricular function; mPB: mobilized 
peripheral blood; SAEs: serious adverse events; BM-MSCs: bone marrow-derived mesenchymal stem 
cells. 
Table 3. Clinical trials of stem cell therapy in refractory angina 
events were distributed evenly between cell and placebo group. CCS class, exercise 
tolerance and angina frequency appear to be improved in both groups at 3 and 6 months 
follow-up. However, the CD34+ stem cell-treated group experienced greater reduction of 
sytomps. Tse et al. randomized 28 “no option” patients, class III or IV angina refractory to 
medical therapy to receive low-dose (1X106 cells/0.1 mL) or high dose (2X106 cells/0.1 mL) 
autologous bone marrow cells or placebo via a direct endomyocardial injection guided by 
electromechanical mapping. Compared with controls, there was a significant increase of 
total exercise time, left ventricle function and a lower NYHA class at 6-month follow-up, but 
CCS class was reduced similarly in both groups. There were no acute or long-term 
complications associated with bone marrow cell implantation. 
More recently, a randomized, double-blind, placebo-controlled trial investigated the effect 
of intra-myocardial bone marrow cell injection on myocardial perfusion and LV function. 
The study population consisted of patients with severe angina pectoris despite optimal 
medical therapy and myocardial ischemia in at least 1 myocardial segment as assessed by 
SPECT and all patients were ineligible for conventional revascularization as determined by 
an independent expert. The intra-myocardial injections of 100X106 autologous bone marrow-
derived mononuclear cells or placebo (randomly assigned in a 1:1 ratio) were delivered after 
electromechanical mapping using NOGA system. In this trial, bone marrow cell injection 
resulted in a significant improvement in angina symptoms, quality of life, and exercise 
capacity, in line with precedent trials (Van Ramshots J). 
The Safety and Efficacy of Autologous Endothelial Progenitor Cells CD133+ for Therapeutic 
Angiogenesis (PROGENITOR) trial is currently ongoing in Spain and will provide more 
information regarding the potential benefit of CD133+ to produce a clinically meaningful 
angiogenic response (see also www.clinicaltrial.com). 
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7.5 The road ahead of cell therapy 
The current state of therapeutic angiogenesis certainly still leaves many questions 
unanswered.  It is of paramount importance that the treatment is delivered safely. Direct IM 
and IC administration have demonstrated acceptable safety profiles in these early trials, and 
may represent a major advance over surgical thoracotomy. Once the treatment is 
administered, assessing the benefit remains a critical issue. Exercise testing, evaluation of 
angina parameters, and myocardial perfusion are routinely used to assess for bioactivity, 
but which most reliably endpoint reflects efficacy remains unknown.  
While therapeutic angiogenesis is not ready to become part of routine therapy for refractory 
angina, it is crucial that we continue to learn from both encouraging and disappointing 
clinical and preclinical studies. The combined efforts of bench and clinical researchers will 
ultimately answer to the question whether cell therapy will be a suitable strategy for 
patients with refractory angina. 
8. Conclusions 
Refractory angina is still a very debilitating condition, with a negative impact on patient’s 
prognosis and social costs. Recent advancements in pharmacological and non-
pharmacological therapy open new perspectives for these patients. If promising results 
recently achieved by different approaches will be confirmed in the near future, it is likely 
that the next generation of physicians dealing with such a debilitating illness will have more 
effective strings in their bow. 
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